Komplexe Hypophysenerkrankungen

  • C. Kasperk


Eine 32-jährige Patientin mit Kinderwunsch wurde zur Abklärung von Unregelmäßigkeiten der Penodenblutungen vorgestellt, die vor 18 Monaten erstmals aufgetreten waren. Seit 3 Monaten war die Patientin amenorrhoisch. Eine gynäkologIsche Untersuchung ergab keine Auffälligkeiten. Die Patientin hatte keine vorbestehenden Erkrankungen oder weitere Beschwerden und nahm keinerlei Medikamente ein. Der klinische Untersuchungsbefund und die laborchemischen Befunde einschließlich der basalen Serumspiegel für TSH und Schilddrüsenhormone waren unauffällig.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


Literatur zu Abschn. 7.1

  1. Bevan J.S., Adams C.B., Burke C.W., Morton K.E., Molyneux A.J., Moore R.A., Esiri U.M. (1987) Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumor including preoperative bromocriptine therapy. Clin Endocrinol (Oxt) 26: 541–556CrossRefGoogle Scholar
  2. Burke C.W., Adams C.B., Esiri M.M., Morris C., Bevan J.S. (1990) Transsphenoidal surgery for Cushing’s disease. Clin Endocrinol (Oxt) 33: 525–537CrossRefGoogle Scholar
  3. Cohen D.L., Bevan J.S., Adams C.B. 1989 The presentation and management of pituitary tumors in the lederly. Age Aging 18: 247–252CrossRefGoogle Scholar
  4. Delgrange E., Trouillas J., Maiter D., Donckier J., Tourniaire J. 1997 Sex-related difference in the growth of prolactinomas: a clinical and proliferation study. J Clin Endocrinol Metab 82: 2102–2107PubMedCrossRefGoogle Scholar
  5. Donovan L., Whitaker M.D., Corenblum B. (1993) Natural history of the pituitary incidentaloma. Proceeding of the 75th Annual Meeting of the Endocrine Soc 1993 (Abstract 972)Google Scholar
  6. Hall W.A., Luciano M.G., Doppman J.L., Patronas N.J., Oldfield E.H. (1994) Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 120: 817–820PubMedCrossRefGoogle Scholar
  7. Kovacs K., Horvath E. 1987 Pathology of pituitary tumors. Endocrinol Metab Clin North Am 16: 609–645Google Scholar
  8. Liuzzi A., Dallabonzana O., Oppizzi G.: Is there areal medical treatment for the nonsecreting pituitary adenomas? In: Faglia G., Beck-Peccoz P., Ambrosi B. (eds): Pituitaryadenomas: new trends in basic and clinical research. Amsterdam, Niederlande, Elsevier 1991, S. 383–390Google Scholar
  9. Molitch M.E., Russell E.J. 1990 The pituitary incidentaloma. Ann Intern Med 112: 925–931PubMedCrossRefGoogle Scholar
  10. Reincke M., Allolio B., Saeger W., Menzel J., Winkelmann W. 1990 The incidentaloma of the pituitary gland. Is neurosurgery required? JAMA 263: 2772–2776PubMedCrossRefGoogle Scholar
  11. Werder K. von, Faglia G. 1992 Potential indications for octreotide in endocrinology. Metabolism 41(Suppl 2):91–98CrossRefGoogle Scholar

Literatur zu Abschn. 7.2

  1. Burger H.G. (1993) Clinical utility of inhibin measurements. J Clin Endocrinol Metab 76: 1391–1396PubMedCrossRefGoogle Scholar
  2. Burman P., Broman J.E., Hetta J., Wiklund I., Erfurth E.M., Hagg E., Karlsson F.A. (1995) Quality of life in adults with growth hormone deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 80: 3585–3590PubMedCrossRefGoogle Scholar
  3. Chan J.M., Stampfer M.J., Giovanucci E. et al. (1998) Plasma insulin-like growth factor 1 and prostate cancer risk: a prospective study. Science 279: 563–566PubMedCrossRefGoogle Scholar
  4. Cuneo R.C., Judd S., Wallace J.D. (1998) The Australian multicenter trial of growth hormone treatment in GH-deficient adults. J Clin Endocrinol Metab 83: 107–116PubMedCrossRefGoogle Scholar
  5. de Boer H., Blok G.J., Popp C., Sips A., Lips P., van der Veen E. (1998) Intestinal calcium absorption and bone metabolism in young adult men with childhood-onset growth hormone deficiency. J Bone Miner Res 13: 245–252PubMedCrossRefGoogle Scholar
  6. Markussis V., Beshyah S.H., Fisher C., Sharp P., Nicolaides A.N., Johnston D.G. (1992) Detection of premature atherosclerosis by high resolution ultrasonography in symptom free hypopituitary adults. Lancet 340: 1188–1192PubMedCrossRefGoogle Scholar
  7. Nieschlag E., Behre H.M. (1996) Therapie mit Testosteron. In: Nieschlag E. (Hrsg) Andrologie. Springer Berlin Heidelberg New York Tokyo, S 315–329Google Scholar
  8. Ng S.T., Zhou J., Adesanya O.O., Wang J., LeRoith D., Bondy C.A. (1997) Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nature Med 3: 1141–1144PubMedCrossRefGoogle Scholar
  9. Rosen T., Bengtsson B.A. (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336: 285–288PubMedCrossRefGoogle Scholar
  10. Smith L.E.H., Kopchick J.J., Chen W. et al. (1997) Essential role of growth hormone in ischemia-induced retinal neovascularisation. Science 276: 1706–1709PubMedCrossRefGoogle Scholar
  11. Toogood A.A., O’Neill P.A., Shalet S.M. (1996) Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 81: 460–465PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • C. Kasperk

There are no affiliations available

Personalised recommendations